A disruptive life-saving solution for early detection of lung edema in heart failure patients

2026-07-22

Heart failure (HF) is a major global cause of death, affecting over 26M people, and it represent the most common cause of hospitalisation for people over 65. Over 90% of hospitalisations and deaths in HF patients are caused by lung fluid congestion, a condition caused by the retention of fluids due to the reduced cardiac pumping ability, which can lead to severe pulmonary edema. Current diagnostic practices for detection of lung fluid congestion are mostly inaccurate, meaning that the condition can only be detected in its advanced stages when emergency hospitalisation is required. This results in a high rate of mortality (30% in the EU) and high treatment costs (€11,300 per person on average). CardioSet introduces a non-invasive monitoring system, EGM, that detects lung fluid accumulation at an early and asymptomatic stage in HF patients. EGM comprises two sets of strategically placed electrodes inside a wearable vest, and a lung fluid monitoring software that automatically sends alerts to a desktop or mobile application when accumulation is detected. EGM enables early detection and pre-emptive interventions, reducing mortality and hospitalisation rate. The technique provides 98% accuracy and a 25-fold increase in sensitivity over incumbent techniques whilst being 50% more cost-effective. CardioSet aim to introduce EGM to market to save lives across the globe. During the phase 1 feasibility study, CardioSet will establish a sound go-to-market strategy and supply chain, and will draft further development plans. During the second phase of the innovation project, CardioSet will optimise and miniaturise device components, optimize the software user-interface, and perform clinical validation with partner hospitals.

Israel

2026-02-01